Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Coronary Microvascular Dysfunction: early-phase trial registry
5 of 8 indexed Coronary Microvascular Dysfunction trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Coronary Microvascular Dysfunction: 8 US clinical trials tracked, 5 recruiting.
Coronary Microvascular Dysfunction is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Amir Lerman, running 1 of these trials.
Enrollment posture brief
Registry condition coronary-microvascular-dysfunction
OPEN 5 | RECR 63% | LATE 0 | EARLY 2 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Coronary Microvascular Dysfunction lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Coronary Microvascular Dysfunction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Coronary Microvascular Dysfunction is recruiting above its size-band peers.
5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Coronary Microvascular Dysfunction trials is spread across many organizations.
Amir Lerman accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Coronary Microvascular Dysfunction trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Coronary Microvascular Dysfunction research leans observational.
3 interventional and 5 observational studies make up this index (37.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Coronary Microvascular Disease (CMD) Registry
Medstar Health Research Institute
NCT05960474
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Cedars-Sinai Medical Center
NCT03876223
Improving Coronary Vascular Health in Women
Massachusetts General Hospital
NCT06843902
Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution
The Cleveland Clinic
NCT06795035
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
Mayo Clinic
NCT07093528
The DISCOVER INOCA Prospective Multi-center Registry
Yale University
NCT05288361
Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Amir Lerman
NCT04523168
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Lisata Therapeutics
NCT03508609
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Coronary Microvascular Dysfunction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Coronary Microvascular Dysfunction trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Coronary Microvascular Dysfunction page
8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Coronary Microvascular Dysfunction trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amir Lerman sponsors the most Coronary Microvascular Dysfunction trials on record, review their full trial history before evaluating a specific study. See Amir Lerman's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Microvascular Dysfunction condition card totals 8 registered trials; most-linked intervention The Neovasc Reducer™ System; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.